Lyell Immunopharma (LYEL) Change in Account Payables (2020 - 2026)
Lyell Immunopharma recorded quarterly Change in Account Payables of $2.4 million in Q1 2026, up 633.23% quarter-over-quarter from $325000.0 in Q4 2025, and up 244.07% year-over-year from $692581.6 in Q1 2025.
Lyell Immunopharma's Change in Account Payables history runs 7 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- In Q1 2026, Change in Account Payables rose 244.07% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $1.7 million (up 135.56% YoY), while the FY2025 annual figure was -$2.3 million, up 27.67% from the prior year.
- Change in Account Payables came in at $2.4 million for Q1 2026 at Lyell Immunopharma, up from $325000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $2.9 million in Q1 2022 to a low of -$2.0 million in Q4 2024.
- A 5-year average of -$62294.1 and a median of -$231000.0 in 2025 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables surged 363.25% in 2022 and slumped 6230.43% in 2023, its largest moves.
- Lyell Immunopharma's Change in Account Payables stood at -$526000.0 in 2022, then soared by 180.8% to $425000.0 in 2023, then sank by 579.06% to -$2.0 million in 2024, then surged by 115.96% to $325000.0 in 2025, then surged by 633.23% to $2.4 million in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $2.4 million, $325000.0, and -$779000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Lyell Immunopharma | 373.31 Mn | 373.31 Mn | - | 2.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.38 Mn |
| Mar 31, 2026 | 2.38 Mn |
| Dec 31, 2025 | 325,000.00 |
| Dec 31, 2025 | 325,000.00 |
| Sep 30, 2025 | -779,000.00 |
| Sep 30, 2025 | -779,000.00 |
| Jun 30, 2025 | -231,000.00 |
| Jun 30, 2025 | -231,000.00 |
| Mar 31, 2025 | -1.65 Mn |
| Mar 31, 2025 | -1.65 Mn |
| Dec 31, 2024 | -2.04 Mn |
| Dec 31, 2024 | -2.04 Mn |
| Sep 30, 2024 | -568,000.00 |
| Sep 30, 2024 | -568,000.00 |
| Jun 30, 2024 | -517,000.00 |
| Jun 30, 2024 | -517,000.00 |
| Mar 31, 2024 | -113,000.00 |
| Mar 31, 2024 | -113,000.00 |
| Dec 31, 2023 | 425,000.00 |
| Dec 31, 2023 | 425,000.00 |
| Sep 30, 2023 | -1.41 Mn |
| Sep 30, 2023 | -1.41 Mn |
| Jun 30, 2023 | 380,000.00 |
| Jun 30, 2023 | 380,000.00 |
| Mar 31, 2023 | 2.07 Mn |
| Mar 31, 2023 | 2.07 Mn |
| Dec 31, 2022 | -526,000.00 |
| Dec 31, 2022 | -526,000.00 |
| Sep 30, 2022 | 23,000.00 |
| Sep 30, 2022 | 23,000.00 |
| Jun 30, 2022 | -1.77 Mn |
| Jun 30, 2022 | -1.77 Mn |
| Mar 31, 2022 | 2.94 Mn |
| Mar 31, 2022 | 2.94 Mn |
| Dec 31, 2021 | 99,000.00 |
| Dec 31, 2021 | 99,000.00 |
| Sep 30, 2021 | -988,000.00 |
| Sep 30, 2021 | -988,000.00 |
| Jun 30, 2021 | 346,000.00 |
| Jun 30, 2021 | 346,000.00 |
| Mar 31, 2021 | 634,000.00 |
| Mar 31, 2021 | 634,000.00 |
| Dec 31, 2020 | 338,000.00 |
| Dec 31, 2020 | 338,000.00 |
| Sep 30, 2020 | -293,000.00 |
| Sep 30, 2020 | -293,000.00 |